We are submitting herewith the copy of monitoring agency report for the quarter ended 31st December, 2025
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs (India) Limited has submitted the quarterly Monitoring Agency Report for the three months ended 31 December 2025, as required under SEBI listing regulations. The report was issued by Infomerics Valuation and Rating Limited, the appointed Monitoring Agency, on 10 February 2026. It pertains to the company's Rights Issue of equity shares aggregating to Rs. 49.92 crore. The Monitoring Agency has reported 'No Deviation' from the stated objects of the issue, confirming that the funds raised are being utilized in line with what was originally disclosed to shareholders. The report has also been hosted on the company's website at www.kilitch.com.
This is a routine compliance filing and carries no negative news. The 'No Deviation' confirmation is mildly reassuring for shareholders as it indicates the company is using the Rs. 49.92 crore raised via the Rights Issue as originally promised, with no diversion of funds.